Isolation and characterization of the mannose receptor from human liver potentially involved in the plasma clearance of tissue‐type plasminogen activator

Marlies Otter, PETRA Žočková, Johan Kuiper, Theo J. C. Van Berkel, Marrie M. Barrett‐Bergshoeff, Dingeman C. Rijken – 1 July 1992 – Various studies have shown that mannose receptors rapidly eliminate glycoproteins and microorganisms bearing high mannose–type carbohydrate chains from the blood circulation. The purpose of this study was to characterize the mannose receptor in the liver, which in vivo is involved in the rapid clearance of tissue‐type plasminogen activator from the circulation.

Plasma atrial natriuretic peptide and renin‐aldosterone in patients with cirrhosis and ascites: Basal levels, changes during daily activity and nocturnal diuresis

Marios Z. Panos, John V. Anderson, Nadia Payne, Peter Langley, Jeremy D. H. Slater, Lesley Rees, Roger Williams – 1 July 1992 – Measurements of plasma atrial natriuretic peptide concentrations at 8 AM showed raised levels in 21 patients with cirrhosis and ascites (10.5 ± 0.8 pmol/L) compared with levels in 10 age‐matched controls (4.1 ± 0.64 pmol/L; p < 0.0001). In eight patients and 10 controls, atrial natriuretic peptide, plasma renin activity, plasma aldosterone and urinary sodium excretion were measured every 4 hr for 24 hr.

Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival

Luigi Barbara, Giovanna Benzi, Stefano Gaiani, Fabio Fusconi, Gianni Zironi, Sebastiano Siringo, Alessandra Rigamonti, Carlotta Barbara, Walter Grigioni, Alighieri Mazziotti, Luigi Bolondi – 1 July 1992 – We analyzed the growth pattern of tumor masses and the survival of 39 asymptomatic Italian patients with a total of 59 small (⩽ 5 cm in diameter) hepatocellular carcinomas arising from cirrhosis. The total length of the observation period ranged from 90 to 962 days, with an average of 364 ± 229 (mean ± S.D.).

Sodium benzoate in the treatment of acute hepatic encephalopathy: A double‐blind randomized trial

S. Sushma, S. Dasarathy, Rakesh K. Tandon, Satish Jain, Surya Gupta, Mahender S. Bhist – 1 July 1992 – A prospective randomized double‐blind study was conducted to evaluate the efficacy of sodium benzoate in the treatment of acute portal‐systemic encephalopathy. Seventy‐four consecutive patients with cirrhosis or surgical portasystemic anastamosis and hepatic encephalopathy of less than 7 days duration were randomized to receive lactulose (dose adjusted for 2 or 3 semiformed stools/day) or sodium benzoate (5 gm twice daily).

Lipopolysaccharide treatment of rats alters antigen expression and oxidative metabolism in hepatic macrophages and endothelial cells

Thomas W. Mc Closkey, Jeanine A. Todaro, Debra L. Laskin – 1 July 1992 – Endothelial cells and macrophages are located within the hepatic sinusoids. These two cell types play an important role in the clearance of bacterially derived lipopolysaccharide from the portal circulation. Our laboratory has previously demonstrated that treatment of rats with lipopolysaccharide results in the accumulation of macrophages in the liver that display properties of activated mononuclear phagocytes. This study was designed to analyze the effects of lipopolysaccharide on hepatic endothelial cells.

Ethinylestradiol increases volume and decreases sinusoidal membrane surface in the rat liver: A stereological analysis

Beat Hornstein, Lukas Stammler, Leonardo Bianchi, Lukas Landmann – 1 July 1992 – Structural alterations of liver parenchyma caused by ethinylestradiol, a synthetic estrogen known to induce cholestasis and to act as a tumor promoter factor, were investigated. Male rats treated with 17α‐ethinylestradiol (5 mg/kg body weight for 5 days) were compared with controls (n = 5 each). After perfusion fixation and systematic random sampling, paraffin sections, semithin sections and thin sections were examined observing standard stereological techniques.

Long‐term follow‐up of patients with chronic hepatitis C treated with α‐interferon

Michiko Shindo, Adrian M. di Bisceglie, Jay H. Hoofnagle – 1 June 1992 – We reanalyzed the results of a pilot study of recombinant α‐interferon therapy for chronic non‐A, non‐B hepatitis in light of the recent discovery of the hepatitis C virus and the development of diagnostic assays for this agent. Stored serum samples from 10 patients treated between 1984 and 1986 were tested for antibody to hepatitis C virus and hepatitis C virus RNA before, during and after therapy.

Effects of vasopressor agents and epoprostenol on systemic hemodynamics and oxygen transport in fulminant hepatic failure

Julia A. Wendon, Phillip M. Harrison, Richard Keays, Alexander E. Gimsson, Graeme J. M. Alexander, Roger Williams – 1 June 1992 – Hypotension is a serious complication in patients with fulminant hepatic failure, because it is associated with tissue hypoxia and a further compromise to end‐organ function. In this study we investigated the effects of epinephrine and norepinephrine on hemodynamics and oxygen transport variables in 30 patients with fulminant hepatic failure. All had a mean arterial pressure of less than 60 mm Hg, despite adequate intravascular filling pressures.

Endocrine mechanisms for the formation of sex‐related differences in hepatic estrogen receptor content and their significance for the realization of an estrogen effect on angiotensinogen blood level in rats

Lidia L. Ignatenko, Guranda D. Mataradze, Victor B. Rozen – 1 June 1992 – The use of a modified, adequate method of quantification of estrogen receptors has permitted us to prove the existence of sex‐specific peculiarities in rat liver estrogen reception and their significance for the realization of sex‐dependent changes in angiotensinogen plasma level after estrogenization. Endocrine mechanisms for the formation of sex‐related differences in hepatic estrogen receptor content in rats were investigated in detail.

Subscribe to